جستجوی مقالات مرتبط با کلیدواژه « سیتاگلیپتین » در نشریات گروه « زیست شناسی »

Fatty liver disease causes accumulation of excess fat in liver cells. Berberine has antioxidant and anti-inflammatory activities, and Sitagliptin is a DPP-4 inhibitor that increases the function of incretin hormones. In this study biological activities of Berberine and Sitagliptin for the treatment of fatty liver in diabetic Sprague-Dawley rats were investigated. The therapeutic effects of Sitagliptin and Berberine on fatty liver in diabetic rats by Alloxan injection with a single dose of 100 mg/kg were done with the following groups. Groups include 1: control (physiology serum as Alloxan solvent); 2: model (fatty liver + Alloxan); 3: Sitagliptin (fatty liver + Alloxan and Sitagliptin 10 mg/kg); 4: Berberine (fatty liver + Alloxan and Berberine 150mg/kg); 5: Berberine/Sitagliptin (fatty liver + Alloxan and Sitagliptin 5 mg/kg and Berberine 75 mg/kg). After the treatment, the liver tissue separated and weighed. Levels of Liver triglyceride, cholesterol and GLUT4 gene expression in liver tissue measured by real-time PCR method. The level of GLUT4 gene expression levels increased in the treatment groups compared to the model group, but a significant difference was seen only in the co-administration group with the model group (p < 0.05). There was a significant decrease in the amount of liver cholesterol in the treatment groups compared to the model group (p < 0.01). Hepatic triglyceride decreased in the treatment groups, but only in the co-administration group, a significant difference was seen with the model group (p < 0.05). Berberine and Sitagliptin, especially when prescribed together with the increased expression of GLUT4 and the reduction of liver cholesterol and triglycerides, have a favorable effect on lipid metabolism and can be considered as an effective treatment for hyperlipidemia and fatty liver.

Hepatic insulin resistance is associated with NAFLD and it is a major factor in the pathogenesis of type 2 diabetes and metabolic syndrome. Insulin resistance causes lipolysis in adipose tissue and disturbance in the regulation of lipid metabolism causes fat accumulation in the liver. In this study, the biological activities of Berberine and Sitagliptin to improve insulin resistance and lipid profile in Sprague-Dawley rats with type 2 diabetes was investigated. groups include 1: control (physiological serum as an alloxan solvent); 2: model (fatty liver + Alloxan); 3: Sitagliptin (fatty liver + Alloxan and Sitagliptin 10 mg/kg); 4: Berberine (fatty liver + Alloxan and Berberine 150mg/kg); 5: Berberine/Sitagliptin (fatty liver + Alloxan and Sitagliptin 5 mg/kg and Berberine 75 mg/kg). At the end of the treatment period, under anesthesia, Blood sampling done from the heart and lipid profile, glucose and insulin measured. The amount of triglyceride (p < 0.01), cholesterol (p < 0.05), LDL (p < 0.01), FFA (p < 0.05), fasting glucose (p < 0.05) and insulin (p < 0.01) in the coadministration group decreased compared to the model group and HDL increased, which was not significant. Berberine and Sitagliptin, especially when administered together, have a favorable effect on lipid metabolism and insulin resistance and can be considered as an effective treatment regimen for hyperlipidemia and fatty liver.